Ten-year-old XNK Therapeutics experiences rapid growing with own GMP facility
XNK Therapeutics has expanded significantly in the past year and now has access to its own GMP-standard production lab.
“We need to have significantly larger capacity to conduct the larger Phase II studies we’re planning. That capacity isn’t available in Sweden, so we’ve built up our own lab in Flemingsberg,” says Johan Liwing, CEO of XNK Therapeutics.
XNK has grown rapidly in recent years and today the company employs almost 30 people in Novum in Flemingsberg. The new GMP facility, with 350sqm of research laboratory space, gives the company better control over its development chain.
Unique technology
XNK Therapeutics was founded in 2012 and is a pioneer in cell therapy. With a unique platform technology, the company focuses primarily on new forms of cancer treatment. The platform enables new cell-based treatments with autologous NK cells.
A clinical investigator-sponsored Phase II study is already being conducted at Karolinska University Hospital, where XNK’s drug candidate is being combined with Sanofi’s anti-CD38 antibody Sarclisa, Isatuximab, for treatment of the severe cancer form multiple myeloma.
“We’re extremely proud of this smaller Phase II study and now we need to increase production capacity. Myeloma is our main focus area, but when we’ve reached the right capacity, there’ll be one or two more [candidates]. It’s important to create a good width outside the blood cancer area,” says Liwing.
XNK Therapeutics is currently conducting a number of projects, including a “proof of concept” study together with the University of Texas MD Anderson Cancer Center in the field of acute myeloid leukemia (AML).
At the beginning of the year, the company raised approximately SEK 130 million in new capital to drive growth.
“It feels great and above all the fact that it’s not only about capital but also provides the addition of competence and production knowledge through NorthX Biologics. We complement each other in a way that enables good synergies,” says Liwing.
“Flemingsberg is the ideal place for us with immediate proximity to everything we need. It’s also home to research in a world-leading research hub and a proximity to a clinic that really knows NK cells.”
Read more about xnktherapeutics.com.
Agnes Török: A Voice for Performance Poetry & Reading Promotion
With roots in Sweden and an international career, Agnes Török has established themselves as one of the most engaging voices in modern poetry. Agnes Török is Sweden’s Reading Ambassador, a spoken word poet, and an author. Recently, they were also appointed as the lead instructor for the new university program in Performance Poetry and Storytelling at The Stockholm University College of Music Education (SMI).
GameHub Flemingsberg: A New Initiative to Create the Gaming Cluster of the Future
The Flemingsberg Science Foundation is launching a business development program in collaboration with Drivhuset Stockholm, associated partners, and Södertörn University as a first step in establishing a gaming cluster in Flemingsberg. The project, named GameHub, aims to facilitate the creation of new gaming companies and strengthen Flemingsberg’s position as a center for game development.
Södertörn University Invests in Social Innovation for Youth in Flemingsberg
Södertörn University has announced that they have been granted funding from the Swedish ESF Council to establish a competence center for social innovation. Flemingsberg continues its development as an innovation hub as researchers, students, and various stakeholders engage in efforts to combat social and economic vulnerability among young people in Södertörn.
Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science
Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund (ERDF) and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.
